Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio (2011 - 2026)

Lineage Cell Therapeutics has reported Asset Utilization Ratio for 16 years, with the latest figure at 0.13 in Q1 2026.

• For the quarter ending Q1 2026, Asset Utilization Ratio rose 56.63% year-over-year to 0.13; the trailing twelve-month figure through Mar 2026 stood at 0.13 (up 56.63% YoY), and the FY2025 full-year result was 0.13, up 45.39% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.13, down from 0.14 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 0.47 in Q3 2022, with the low at 0.06 in Q2 2024.
• Historically, Asset Utilization Ratio has averaged 0.16 across 5 years, with a median of 0.1 in 2023.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 3078.23% — and 2023, when it sank 82.87%.
• Lineage Cell Therapeutics' Asset Utilization Ratio stood at 0.12 in 2022, then declined by 25.17% to 0.09 in 2023, then rose by 4.86% to 0.09 in 2024, then jumped by 58.99% to 0.14 in 2025, then dropped by 7.56% to 0.13 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.13 (Q1 2026), 0.14 (Q4 2025), and 0.12 (Q3 2025), per Business Quant data.